19 results
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
findings. CC8464 demonstrated minimal activity against a broad array of potential targets and off-targets with only one confirmed IC50 less than 10 μM (κ … to by the FDA under the Prescription Drug User Fee Act, as amended (the “PDUFA”), the FDA targets ten months, from the filing date, in which
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
findings. CC8464 demonstrated minimal activity against a broad array of potential targets and off-targets with only one confirmed IC50 less than 10 μM (κ … to by the FDA under the Prescription Drug User Fee Act, as amended (the “PDUFA”), the FDA targets ten months, from the filing date, in which
10-K
2023 FY
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
findings. CC8464 demonstrated minimal activity against a broad array of potential targets and off-targets with only one confirmed IC50 less than 10 μM (κ … to by the FDA under the Prescription Drug User Fee Act, as amended (the “PDUFA”), the FDA targets ten months, from the filing date, in which to complete
8-K
EX-99.1
CHRO
Chromocell Therapeutics Corp.
9 Apr 24
Chromocell Issues Letter to Stockholders from Chief Executive Officer
8:30am
indications with molecules that show no addictive or euphoric properties.
Our core development program targets the NaV1.7 sodium channel, as well as other
8-K
EX-99.1
CHRO
Chromocell Therapeutics Corp.
21 Mar 24
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
9:00am
Exhibit 99.1
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
New Program Targets Estimated $2.5 … eye pain indications include autoimmune diseases, dry eye and neuropathic etiologies. Chromocell’s platform uniquely targets the NaV1.7 channels
424B4
rajikhql1s o0vzzx7k
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
lq68otd5uf8sf 82cg
20 Feb 24
Prospectus supplement with pricing info
5:28pm
DRS/A
7uqi1hna5ghsx
17 Oct 22
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next